Penumbra (NYSE:PEN) Releases Earnings Results, Beats Estimates By $0.09 EPS

Penumbra (NYSE:PEN) issued its quarterly earnings data on Tuesday. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09, Zacks reports. Penumbra had a return on equity of 9.73% and a net margin of 1.17%. The company had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra updated its FY 2025 guidance to EPS.

Penumbra Price Performance

PEN opened at $303.55 on Thursday. The company has a fifty day moving average price of $256.15 and a two-hundred day moving average price of $225.97. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 5.82. The firm has a market capitalization of $11.65 billion, a PE ratio of 892.79, a P/E/G ratio of 1.99 and a beta of 0.53. Penumbra has a 52 week low of $148.00 and a 52 week high of $310.00.

Insider Buying and Selling

In related news, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the transaction, the director now owns 8,530 shares of the company’s stock, valued at $2,058,118.40. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Adam Elsesser sold 15,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the completion of the sale, the chief executive officer now owns 837,582 shares in the company, valued at approximately $203,498,922.72. This trade represents a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,219 shares of company stock valued at $4,426,439 over the last three months. Company insiders own 5.00% of the company’s stock.

Analyst Ratings Changes

PEN has been the subject of several analyst reports. Robert W. Baird lifted their price target on shares of Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a report on Wednesday. Wells Fargo & Company lifted their target price on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $330.00 target price (up from $250.00) on shares of Penumbra in a report on Wednesday. Oppenheimer assumed coverage on Penumbra in a report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 price target for the company. Finally, JPMorgan Chase & Co. upped their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Penumbra has a consensus rating of “Moderate Buy” and an average target price of $292.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.